A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

NCT ID: NCT00455052

Last Updated: 2018-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-31
• Study Completion Date: 2011-12-31

Brief Summary

This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for preliminary anti-tumor activity in these tumor types. The MTD was initially defined as 113 mg CPT equivalents(eq)/m2 in the dose escalation part of the study. However, in the initial expansion phase (Protocol Amendment 11), 11 patients (10 NSCLC patients and 1 gastric cancer patients) were dosed at 113 mg CPT eq/m2 and less bone marrow toxicity was observed as compared to more heavily pre-treated patients in the dose escalation part of the study. Therefore, this amended expansion phase will investigate the safety and anti-tumor effects of a dose of 150 mg CPT eq/m2.

The study will also determine:

• The safety and tolerability of XMT-1001 at 150 mg CPT eq/m2
• The pharmacokinetics (PK) of XMT-1001 (how XMT-1001 behaves in the body) in patients Stage IV non-small cell lung carcinoma (NSCLC) and small cell lung cancer
• Evidence of XMT-1001 anti-tumor activity at 150 mg CPT eq/m2

Detailed Description

This is an open-label study of XMT-1001 administered intravenously over 4 hours every 21 days (1 Cycle). Blood sampling for PK analyses will be performed immediately prior to dosing, and 9 times after dosing. Patients will be assessed for toxicities known to occur with other drugs of this class, such as bone marrow suppression, elevated liver function enzymes, hemorrhagic cystitis, and diarrhea. Tumor imaging will be performed every 2 cycles.

Conditions

Small Cell Lung Cancer; Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

XMT-1001

XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m\^2, the next dose level is 30 mg/m\^2, followed by dose levels: 50 mg/m\^2, 80 mg/m\^2, 120 mg/m\^2, 150 mg/m\^2, and 190 mg/m\^2 until disease progressions or unacceptable side effects are experienced.

Group Type: EXPERIMENTAL

XMT-1001

Intervention Type: DRUG

XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.

Interventions

XMT-1001

XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.

Intervention Type: DRUG

Other Intervention Names

MER-1001

Eligibility Criteria

Inclusion Criteria

1. At least 18 years old

2. Have histological or cytological documentation of one of the following:

A. NSCLC with Stage IV disease according to the American Joint Cancer Commission TNM Staging (7th Edition)

• Have received at least one prior chemotherapy regimen but no more than two chemotherapy regimens for their advanced disease (not containing irinotecan or topotecan).
• Adjuvant chemotherapy will be considered as a prior chemotherapy regimen only if it is completed less than 6 months prior to enrollment.
• Treatment with erlotinib or crizotinib as single agents will not be considered as a chemotherapy regimen for purposes of this trial OR B. SCLC with Stage IV (extensive) or recurrent disease after definitive treatment for limited stage disease according to the American Joint Cancer Commission TNM Staging (7th Edition)1
• Have received at least one prior chemotherapy regimen but no more than two chemotherapy regimens for their advanced disease (not containing irinotecan or topotecan).
• Adjuvant chemotherapy will be considered as a prior chemotherapy regimen only if it is completed less than 6 months prior to enrollment.

3. Patients must be refractory or resistant to standard therapy or for whom standard therapy is not anticipated to be curative and who have progressed through prior regimens.

4. Patients must have measurable disease with at least one lesion that can be accurately measured by Response Evaluation Criteria in Solid Tumors (RECIST). The lesion size must be ≥20 mm by conventional radiological techniques or ≥10 mm by spiral CT scan. Disease in an irradiated field as the only site of measurable disease is acceptable if there has been a clear progression of the lesion. PET scans are not suitable for providing these measurements. For patients who are sensitive to contrast, MRI may be used.

5. Patients with CNS metastases are acceptable provided that the disease has been treated (e.g. surgery, whole brain radiotherapy, stereotactic radiotherapy etc.) and the patient is stable for at least two weeks and does not require steroids (at least one week off steroids). Anti-seizure medication is allowed at the discretion of the treating physician.

6. At least 42 days since administration of mitomycin or nitrosoureas, and 28 days since any other chemotherapy, investigational agent, and/or radiation therapy.

7. Have the following laboratory values:

• Absolute neutrophil count (ANC) ≥1500 cells/mm3
• Platelet count >100,000 cells/mm3
• Hemoglobin ≥9.0 g/dL
• Adequate renal function (serum creatinine ≤2 mg/dL) and creatinine clearance ≥45 mL/min (Calculated by Cockroft and Gault method)
• Adequate hepatic function (bilirubin ≤1.5 mg/dL)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the institutional upper limit of normal (ULN, or

• 5 times the ULN if liver metastases are present)
• Albumin of >3.0 g/dL
• PT and PTT ≤1.5 times the ULN

8. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.

9. Have a life expectancy of at least 3 months.

10. Have signed an informed consent form.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mersana Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Edward Sausville, MD

Role: PRINCIPAL_INVESTIGATOR

University of Maryland Greenebaum Cancer Center

Glen J Weiss, MD

Role: PRINCIPAL_INVESTIGATOR

TGen Clinical Research Services at Scottsdale Healthcare

Lawrence Garbo, MD

Role: PRINCIPAL_INVESTIGATOR

New York Oncology Hematology

Allen Lee Cohn, MD

Role: PRINCIPAL_INVESTIGATOR

Rocky Mountain Cancer Centers

Paul R. Conkling, MD

Role: PRINCIPAL_INVESTIGATOR

Virginia Oncology Associates

William J Edenfield, MD

Role: PRINCIPAL_INVESTIGATOR

Institute for Translational Oncology Research

Donald A. Richards, MD

Role: PRINCIPAL_INVESTIGATOR

Texas Oncology - Tyler

John R. Caton, MD

Role: PRINCIPAL_INVESTIGATOR

Willamette Valley Cancer Institute and Research Center

David A. Smith, MD

Role: PRINCIPAL_INVESTIGATOR

Northwest Cancer Specialists - Vancouver Cancer Center

Hillary H. Wu, MD

Role: PRINCIPAL_INVESTIGATOR

Central Indiana Cancer Centers

Fadi Braiteh, MD

Role: PRINCIPAL_INVESTIGATOR

Comprehensive Cancer Centers of Nevada

Stephen Anthony, MD

Role: PRINCIPAL_INVESTIGATOR

Evergreen Hematology & Oncology

Locations

TGen Clinical Research Services at Scottsdale Healthcare

Scottsdale, Arizona, United States

Rocky Mountain Cancer Centers

Denver, Colorado, United States

Central Indiana Cancer Centers

Indianapolis, Indiana, United States

University of Maryland, Greenebaum Cancer Center

Baltimore, Maryland, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

New York Oncology Hematology

New York, New York, United States

Willamette Valley Cancer Institute and Research Center

Springfield, Oregon, United States

Institute of Translational Oncology Research

Greenville, South Carolina, United States

Texas Oncology - Tyler

Tyler, Texas, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

Evergreen Hematology & Oncology

Spokane, Washington, United States

Vancouver Cancer Center

Vancouver, Washington, United States

Countries

United States

References

Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, Papisov MI. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Mol Pharm. 2004 Sep-Oct;1(5):375-82. doi: 10.1021/mp0499306.

Reference Type: BACKGROUND

PMID: 16026008 (View on PubMed)

Other Identifiers

MER-001

Identifier Type: -

Identifier Source: org_study_id